Yvonne Remde

606 total citations · 1 hit paper
8 papers, 451 citations indexed

About

Yvonne Remde is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Yvonne Remde has authored 8 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Radiology, Nuclear Medicine and Imaging, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Oncology. Recurrent topics in Yvonne Remde's work include Radiopharmaceutical Chemistry and Applications (7 papers), Peptidase Inhibition and Analysis (4 papers) and Prostate Cancer Treatment and Research (4 papers). Yvonne Remde is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (7 papers), Peptidase Inhibition and Analysis (4 papers) and Prostate Cancer Treatment and Research (4 papers). Yvonne Remde collaborates with scholars based in Germany, Hungary and Czechia. Yvonne Remde's co-authors include Klaus Kopka, Martin Schäfer, Oliver Neels, Matthias Eder, Ulrike Bauder‐Wüst, Miriam Müller, Michael Eisenhut, Ute Hennrich, Ali Afshar‐Oromieh and Uwe Haberkorn and has published in prestigious journals such as Journal of Medicinal Chemistry, The Journal of Organic Chemistry and European Journal of Nuclear Medicine and Molecular Imaging.

In The Last Decade

Yvonne Remde

7 papers receiving 449 citations

Hit Papers

Novel Preclinical and Radiopharmaceutical Aspects of [68G... 2014 2026 2018 2022 2014 100 200 300

Peers

Yvonne Remde
Donika Plyku United States
Florette Reyneke South Africa
Johncy Mahapane South Africa
Muhammad Junaid Niaz United States
Akrita Bhatnagar United States
Donika Plyku United States
Yvonne Remde
Citations per year, relative to Yvonne Remde Yvonne Remde (= 1×) peers Donika Plyku

Countries citing papers authored by Yvonne Remde

Since Specialization
Citations

This map shows the geographic impact of Yvonne Remde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yvonne Remde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yvonne Remde more than expected).

Fields of papers citing papers by Yvonne Remde

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yvonne Remde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yvonne Remde. The network helps show where Yvonne Remde may publish in the future.

Co-authorship network of co-authors of Yvonne Remde

This figure shows the co-authorship network connecting the top 25 collaborators of Yvonne Remde. A scholar is included among the top collaborators of Yvonne Remde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yvonne Remde. Yvonne Remde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Zitzmann-Kolbe, Sabine, Yvonne Remde, Balázs G. Madas, et al.. (2025). Biodistribution of free Francium-221 and Bismuth-213 in Tumour-bearing SCID mice after successful development of Actinium-225/Francium-221 radionuclide generator Set-up. European Journal of Nuclear Medicine and Molecular Imaging. 53(1). 633–646.
2.
Schäfer, Martin, Ulrike Bauder‐Wüst, Mareike Roscher, et al.. (2025). Structure–Activity Relationships and Biological Insights into PSMA-617 and Its Derivatives with Modified Lipophilic Linker Regions. ACS Omega. 10(7). 7077–7090. 4 indexed citations
3.
Bauder‐Wüst, Ulrike, Martin Schäfer, Yvonne Remde, et al.. (2023). Synthesis of tritium-labeled Lu-PSMA-617: Alternative tool for biological evaluation of radiometal-based pharmaceuticals. Applied Radiation and Isotopes. 197. 110819–110819. 1 indexed citations
4.
Cardinale, Jens, Mareike Roscher, Martin Schäfer, et al.. (2020). Development of PSMA-1007-Related Series of 18F-Labeled Glu-Ureido-Type PSMA Inhibitors. Journal of Medicinal Chemistry. 63(19). 10897–10907. 24 indexed citations
5.
Makarem, Ata, et al.. (2019). HBED-NN: A Bifunctional Chelator for Constructing Radiopharmaceuticals. The Journal of Organic Chemistry. 84(11). 7501–7508. 18 indexed citations
6.
Bauder‐Wüst, Ulrike, Martin Schäfer, Jana Schmidt, et al.. (2019). Designing tracers for PET imaging of the urokinase‐type plasminogen activator receptor from a cyclic uPA‐derived peptide: first in vitro evaluations. Journal of Labelled Compounds and Radiopharmaceuticals. 62(8). 483–494. 1 indexed citations
7.
Cardinale, Jens, René Martin, Yvonne Remde, et al.. (2017). Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer. Pharmaceuticals. 10(4). 77–77. 86 indexed citations
8.
Eder, Matthias, Oliver Neels, Miriam Müller, et al.. (2014). Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. Pharmaceuticals. 7(7). 779–796. 317 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026